Consistently, we found that both CD4+ and CD8+ T cells were able to facilitate short-term BsAb-induced target tumor cell lysis, with CD4+ T cell-mediated target cell lysis only being slightly less robust than that for CD8+ T cells. The gene discussed is CD4; the disease is neoplasm.